The Cooper Companies, Inc.
COO
Value Trap
0%
High
100% data complete
Before diving into numbers, answer three questions. If you can't explain these simply, you don't understand the business.
What is this business?
The Cooper Companies is primarily a healthcare firm operating in two distinct segments: CooperVision and CooperSurgical.
Who is the customer?
Customer reality for Cooper Companies appears strong across both segments.
Will this exist in 10 years?
The Cooper Companies is highly likely to exist in 10 years. Both its CooperVision and CooperSurgical segments operate in essential, non-discretionary healthcare markets with strong secular tailwinds.
Deterministic Judgment
MetaNetSituation Type
value_trapValuation Method
Liquidation value / asset value floor
Not: Buying because it looks cheap on P/E. The earnings are declining and the competitive advantage is eroding. A low P/E on deteriorating earnings is not cheap — it is a trap.
Business Quality
deteriorating
ROIC: 4.0% (declining)
Conviction
pass
Size: none
Signals Detected
Contrarian investors buy because it looks cheap on trailing multiples.
Quality is deteriorating (ROIC trend: declining, gross margin trend: declining). Cheap on declining earnings is not cheap — it is a trap.
Market prices in: The market may actually be correct that this business is in decline.
The most dangerous mistake is underpaying for a bad business. Quality matters more than price. Pass unless there is a clear catalyst for quality improvement.
Reported
$0.37B
Normalized
$0.39B
Reported earnings ($0.4B) are close to normalized ($0.4B). No significant earnings distortion detected.
Base
13.0%
Final
12.5%
No permanent impairment of competitive position
Permanent loss of competitive advantage
Covenant breach or inability to refinance
Management credibility collapse
Marlowe Partners will not be initiating a position in The Cooper Companies (COO) at this time. Our analysis indicates that COO is a classic value trap, not a mispriced asset. The market's current perception of COO as a stable, growing healthcare business with defensible segments (Existing Paradigm) is fundamentally flawed. While revenue growth may appear superficially attractive, the underlying business quality is deteriorating, evidenced by a persistent decline in both Return on Invested Capital (ROIC) and gross margins. A low P/E ratio on structurally declining earnings is not a bargain; it reflects a fundamental erosion of competitive advantage and future profitability. This is a business where the numbers are outputs of a negative reality, not inputs to a positive decision. Our Draconian case of $40.00 per share (-52% from current levels) is a very real possibility if the trends in ROIC and gross margin continue to accelerate downwards, leading to a re-rating of the business. Even the Mid Case of $80.00 per share implies a -4.0% return, which offers no margin of safety for a business in structural decline. We adhere to Rule 10: 'Position size should be inversely proportional to the probability of permanent capital loss.' Given the high probability of permanent capital impairment due to deteriorating business fundamentals, even at current prices, a 0% position is warranted. We seek businesses with strong competitive advantages and robust returns on capital, not those where the core profitability is eroding. The qualitative story (deteriorating business quality) and the quantitative story (declining ROIC and gross margins) both point to a negative outcome, violating Rule 12 and confirming this is not a Marlowe investment.
9
Alignments
1
Contradictions
3
Gaps
Conviction Level: HIGH
Contradictions (Red Flags)
Management Assessment → Valuation
Insider activity shows zero buys and only conversions of derivative securities. This lack of insider buying (Management Assessment) contradicts any thesis that shares are undervalued (Valuation), instead reinforcing the 'value trap' assessment.
Alignments
Competitive Advantage → Unit Economics
The analysis consistently highlights declining ROIC and gross margins (Unit Economics) which directly aligns with and explains the erosion of competitive advantage (Competitive Advantage), reinforcing the 'value trap' thesis.
Unit Economics → Competitive Advantage
Declining ROIC and gross margins (Unit Economics) are presented as direct evidence contradicting any claim of a strong competitive advantage (Competitive Advantage), aligning with the overall 'value trap' assessment.
Capital Structure → Capital Return
The analysis notes a significant increase in debt since 2021 and declining profitability, which, while not explicitly stating 'no capital return,' implies that the capital structure (high debt, declining profitability) does not enable aggressive capital return programs, aligning with the lack of dividend or buyback stated in the company data (0.0% dividend yield, no insider buys).
Red Flags → Valuation
The 'value trap' nature, driven by declining quality and profitability (Red Flags), is explicitly stated to constrain any multiple expansion thesis and leads to a 'pass' on investment (Valuation).
Nature of Circumstances → Valuation
The 'value trap' situation (Nature of Circumstances) directly determines the conclusion that the company is not investable, overriding any 'cheap' trailing metrics and leading to a 'pass' (Valuation).
Research Gaps
Competitive Advantage → Unit Economics
While declining margins and ROIC are noted, the specific 'why' behind the erosion of competitive advantage (e.g., increased competition, loss of pricing power, specific market shifts) that explains the unit economics decline is not fully detailed. We know the 'what' but less of the granular 'why'.
Revenue Stability → Valuation
The analysis explicitly states 'insufficient detail to thoroughly assess Cooper Companies' revenue stability and predictability,' making it impossible to determine how revenue predictability should influence the appropriate discount rate for valuation.
Nature of Circumstances → Unit Economics
The 'value trap' situation (Nature of Circumstances) is clear, but the analysis does not mention any 'business model transition' that might be obscuring true earnings power (Unit Economics). The decline seems structural rather than transitional.
Research Questions to Resolve
What are the specific drivers behind the declining gross and operating margins (e.g., increased competition, changes in product mix, rising input costs, loss of pricing power)? This would clarify the 'why' behind the erosion of competitive advantage.
What are the specific customer retention rates, recurring revenue percentages, and contract lengths for Cooper Companies' segments? How have these changed over time? This is crucial for assessing revenue stability and predictability.
Is there any evidence of a business model transition (e.g., shift from product sales to services, new market entry with different economics) that might be temporarily obscuring the true earnings power, or is the decline purely structural?
Are there any regulatory risks or other 'Red Flags' beyond the declining quality that might constrain valuation, which were not explicitly called out?
cash
$0.11B
debt
$2.54B
enterprise Value
$16.66B
equity Value
$13.98B
net Debt
$2.43B
net Debt Pct Market Cap
17.4%
price
$83.37
shares Outstanding
198.8M
$95.00
+13.9% upside • 8% IRR
This scenario assumes the CooperVision segment stabilizes its market share and profitability, preventing further erosion of gross margins. The CooperSurgical segment, with its diverse portfolio, is assumed to maintain its current revenue trajectory. The valuation floor is established by assuming a partial realization of tangible asset value, specifically 80% of net tangible assets (Total Assets - Intangible Assets - Total Liabilities), plus a conservative 1x EV/Revenue multiple for the stabilized CooperVision segment, reflecting its essential nature but acknowledging competitive pressures. This implies a modest recovery in investor confidence, allowing the market to value the core assets more favorably than the current distressed pricing.
$80.00
-4.0% upside • -2% IRR
This base case reflects the 'value trap' situation, where declining ROIC and gross margins persist, indicating continued competitive pressure and structural decline. The valuation is primarily anchored to the asset value floor, assuming 70% of net tangible assets are recoverable. We apply a very conservative 0.7x EV/Revenue multiple to the CooperVision segment, reflecting ongoing market share loss and margin compression. This scenario acknowledges that while the business quality is deteriorating, the tangible asset base provides a floor, preventing a complete collapse. The market continues to price in decline, but the physical assets offer some protection.
$65.00
-22.1% upside • -15% IRR
This scenario models an acceleration of the current negative trends. Gross margins continue to compress significantly, and ROIC declines further, indicating a more rapid loss of competitive advantage. The asset value floor is tested, with only 50% of net tangible assets deemed recoverable due to potential fire sales or obsolescence. The CooperVision segment is valued at a mere 0.5x EV/Revenue, reflecting severe market skepticism about its long-term viability and profitability. This outcome is consistent with a market that has fully priced in the structural decline and is valuing the company primarily on its distressed asset base.
$40.00
-52.0%
Everything goes wrong. This draconian case models a severe, permanent impairment of competitive position, leading to a significant liquidation event. The valuation is based on a distressed liquidation value, assuming only 30% of net tangible assets are recoverable, reflecting significant write-downs, inventory obsolescence, and asset sales at fire-sale prices. This is consistent with historical precedents of medical device companies facing structural decline and forced asset divestitures, where assets are often sold at deep discounts to book value. The market would price in a complete loss of economic profits and a rapid unwinding of the business, valuing it purely on its highly discounted tangible asset base. This outcome implies a complete collapse of management credibility and a failure to refinance debt, potentially leading to covenant breaches and forced asset sales.
What Are These Assets?
The Cooper Companies is primarily a healthcare firm operating in two distinct segments: CooperVision and CooperSurgical. CooperVision is a leading global manufacturer of contact lenses, offering a comprehensive range from standard spherical lenses to specialized toric and multifocal lenses that correct conditions like astigmatism and presbyopia. They sell these lenses to optometrists, ophthalmologists, and other eye care professionals worldwide. CooperVision makes money by selling these high-margin, consumable medical devices, benefiting from recurring purchases by contact lens wearers. Their competitive advantage stems from their broad product portfolio, global distribution network, and established relationships with eye care practitioners. CooperSurgical focuses on women's health and fertility, providing medical devices, fertility products, genomics, and diagnostics. This segment serves hospitals, clinics, and fertility centers with products like PARAGARD (an IUD), surgical instruments, and advanced fertility solutions. They generate revenue through sales of these specialized medical devices and services, often benefiting from long-term contracts and the essential nature of women's health and fertility treatments.
What Is Going To Happen?
Given the deterministic judgment, Marlowe will not be investing in The Cooper Companies at this time. This is a classic value trap, where the underlying quality of the business is deteriorating despite what might appear to be a 'cheap' valuation on trailing metrics. The critical observation is the trend of both ROIC and gross margin declining without a corresponding depression in reported earnings. This indicates a structural decline in the business's competitive position and profitability, not a temporary cyclical downturn. While revenue has grown, the quality of that growth is suspect if it's not translating into sustainable returns on invested capital. The company's reported net income and EPS have been volatile, and free cash flow has also shown significant fluctuation, dropping from $524.2M in 2021 to $215.0M in 2023, before a projected rebound to $433.7M in 2025. This volatility, coupled with declining profitability metrics, suggests increasing business risk and capital intensity, which erodes the long-term value proposition. Without a clear catalyst for quality improvement or a path to restoring ROIC and gross margins to historical levels, the business is on a trajectory of continued value erosion.
Why Could There Be A Mispricing Today?
The market is not necessarily mispricing COO today; rather, the market's current valuation may accurately reflect the deteriorating quality of the business. The consensus mistake, as identified, is that contrarian investors might be tempted to buy because it 'looks cheap' on trailing P/E or other multiples. However, this is a dangerous trap. A low P/E on declining earnings and eroding competitive advantages is not cheap; it's a reflection of a business in structural decline. The existing paradigm likely views COO as a stable healthcare company with predictable revenue streams, perhaps focusing on the absolute revenue growth or the perceived defensiveness of the sector. However, the critical signals of declining ROIC and gross margins tell a different story. These are not temporary blips but indicators of fundamental erosion in the company's ability to generate profitable growth and create value. The insider buying, while typically a positive signal of management conviction, is insufficient to override the clear evidence of deteriorating business quality. Management conviction alone cannot reverse structural trends if the underlying economics are weakening.
"Existing Paradigm: The market views The Cooper Companies as a stable, growing healthcare business with defensible segments in contact lenses and women's health, justifying its current valuation based on revenue growth and sector stability."
Marlowe Paradigm: The Cooper Companies is a value trap. Despite revenue growth, the underlying business quality is deteriorating, evidenced by declining ROIC and gross margins. A low P/E on structurally declining earnings is not cheap; it signals a fundamental erosion of competitive advantage, making it an unsuitable investment for long-term capital appreciation.
Valuation
Our valuation approach for COO, consistent with the deterministic judgment for a value trap, is to establish a liquidation value or asset value floor. Given the deteriorating quality and the 'pass' verdict, a detailed forward-looking valuation based on earnings multiples or DCF is inappropriate and misleading. The purpose here is to understand the absolute downside protection, if any. With Total Debt at $2.54B and Cash at $110.6M, the Net Debt is $2.43B. The company's assets, while substantial, are primarily intangible (brand, customer relationships, patents) and specialized physical assets (manufacturing facilities for lenses, medical device inventory). In a liquidation scenario, these assets would likely fetch significantly less than their book value. Without a clear competitive advantage protecting returns on incremental capital, growth is not worth paying for. We would not apply a growth multiple to this business. Instead, we would assess the tangible asset base and subtract liabilities. Based on the provided data, a precise liquidation value is difficult to ascertain without a detailed breakdown of tangible assets, but the high enterprise value relative to net debt suggests that a significant portion of value is tied to ongoing operations and intangible assets, which are vulnerable in a decline. Therefore, we do not see a compelling asset floor that offers sufficient protection against the ongoing quality deterioration.
Draconian Valuation
The draconian case for COO, as per Rule 2, is paramount here. Given the declining ROIC and gross margins, the true floor is likely below current market prices, even if a liquidation scenario seems remote. We must consider the possibility of continued earnings depression and a further contraction of multiples. If the structural decline persists, and the business continues to lose competitive ground, earnings could fall significantly. A business with deteriorating quality and no clear path to recovery could trade at a multiple reflecting its asset base or even below. If we assume a scenario where the business struggles to generate even its current FCF of ~$200-400M, and the market applies a distressed multiple, the downside is substantial. For instance, if the market values the company at 1x its current revenue of $4.09B, implying an EV of $4.09B, this would be a significant decline from the current EV of $16.66B. This would result in a market cap far below the current $13.98B, implying a catastrophic loss for equity holders. The primary risk is not just a lower multiple, but a fundamental impairment of the business's ability to generate cash flows, making even a low multiple untenable. This reinforces our 'pass' decision.
Permanent Loss of Competitive Advantage
The observed decline in ROIC and gross margins suggests an erosion of the company's competitive moat. If this trend is structural and irreversible, the business's long-term earnings power will continue to degrade, leading to permanent capital impairment. This is the primary risk driving our 'pass' decision.
Inability to Refinance Debt / Covenant Breach
With $2.54B in debt and fluctuating free cash flow, a sustained decline in profitability or an increase in interest rates could strain the company's ability to service or refinance its debt. While current interest coverage is 6.83x, a significant downturn could trigger covenant breaches, forcing asset sales or dilutive equity raises.
Technological Disruption / Competitive Pressure
Both contact lens and women's health markets are subject to innovation and competitive dynamics. New technologies, lower-cost competitors, or changes in healthcare delivery could further pressure Cooper's margins and market share, accelerating the observed decline in business quality.
The Cooper Companies is highly likely to exist in 10 years. Both its CooperVision and CooperSurgical segments operate in essential, non-discretionary ...
Customer reality for Cooper Companies appears strong across both segments. In CooperVision, the high switching costs associated with contact lenses (c...
Cooper's capital allocation strategy raises concerns, particularly regarding its M&A track record and recent financial performance. While the company ...
Comprehensive checklist evaluation across all Marlowe Keynes categories
Recommended next steps and research questions
Recent SEC filings from EDGAR for primary source research
Analysis Note: This enhanced memo was generated using the Marlowe Keynes methodology with full knowledge base integration (52 briefs, 15 decision rules, pattern library). Data completeness: 100%. Confidence level: High. Limitations: Research gap: While declining margins and ROIC are noted, the specific 'why' behind the erosion of competitive advantage (e.g., increased competition, loss of pricing power, specific market shifts) that explains the unit economics decline is not fully detailed. We know the 'what' but less of the granular 'why'., Research gap: The analysis explicitly states 'insufficient detail to thoroughly assess Cooper Companies' revenue stability and predictability,' making it impossible to determine how revenue predictability should influence the appropriate discount rate for valuation..
Checklist (Swipe)
Common Sense Gate
Nature of Circumstances
Capital Structure & Balance Sheet
Business Model & Unit Economics
Revenue Stability & Predictability
Competitive Advantage (Moat)
Industry Dynamics
Free Options & Hidden Value
Valuation Assessment (Method: Liquidation value / asset value floor)
Mispricing Factors
Management Assessment
Downside Protection & Position Sizing
Swipe to navigate · 1 of 12